Citations

Clear

9383 citation(s) found for "Thomas, PS".

Reaffirming the importance of nomenclature stability for Candida auris and its associated disease of candidiasis
Zhang, Sean X. , Hoog, Sybren G. de, Denning, David W. , Ahmed, Sarah , Alastruey-Izquierdo, Ana, Arendrup, Maiken Cavling, Borman, Andrew M. , Chen, Sharon, Chowdhary, Anuradha , Colgrove, Robert C. , Cornely, O., Filkins, Laura , Gangneux, Jean-Pierre, Gené, Josepa, Groll, A. H., Guillot, Jaques, HAASE, G., Jagielski, Tomasz , Kandemir, Hazal, Kidd, Sarah , Kwon-Chung, June, Mendoza, Leonel, Nguyen, M. Hong, Song, Yinggai , Stielow, J. Benjamin, Vilela, Raquel, Vitale, Roxana G. , Wengenack, Nancy L. , White, P. Lewis, Ostroski-Zeichner, Luis, Walsh, Thomas J., Alastruey‐Izquierdo, Ana , Arendrup, Maiken Cavling , Kandemir, Hazal , de Hoog, Sybren , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Filkins, Laura , Gené, Josepa , Groll, Andreas H , Halliday, Catriona , Hoenigl, Martin , Jagielski, Tomasz , Kandemir, Hazal , Kidd, Sarah E , Kus, Julianne V , Kwon-Chung, Kyung J , Lockhart, Shawn R. , Meis, Jacques F , Mendoza, Leonel , Nguyen, M Hong , Song, Yinggai , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Walsh, Thomas J , Zhang, Sean X , Ahmed, Sarah A , Cornely, Oliver A. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Groll, Andreas H. , Haase, Gerhard , Hawksworth, David L. , Hay, Roderick J. , Hoenigl, Martin , Hubka, Vít , Kus, Julianne V. , Kwon‐Chung, June , Meyer, Wieland , Sorrell, Tania Christine , Stielow, J. Benjamin , Vilela, Raquel, Ostrosky‐Zeichner, Luis

Mayo Clinic

Journal of Clinical Microbiology | December 23, 2025 | Volume: 64 | Issue: 2 | Pages: No page available

10.1128/jcm.01550-25 | PMID 41432443 Get It

Proposed Development of a New Staging System for Hearing Loss: Countermeasure 2 of the Hearing Health Collaborative
Carlson, Matthew L., Zwolan, Teresa A. , Cosetti, Maura K. , Gubbels, Samuel P., Hashmi, Ardeshir Z. , Holcomb, Meredith A. , Jilla, Anna Maria, Kelley, Barbara, Lohse, Christine M. , Marinelli, John P. , McKee, Michael , Moody-Antonio, Stephanie A., Miller, Erin L. , Nassiri, Ashley M. , Reed, Nicholas S. , Spankovich, Christopher , Tieben, John, Zeitler, Daniel M. , Sydlowski, Sarah A., Tieben, John E, Carlson, Matthew L. , Bush, Matthew L. , Dunn, Camille C. , Gurgel, Richard Klaus , Hunter, Jacob B. , Jilla, Anna Marie , Moody‐Antonio, Stephanie , Miller, Erin L., Sladen, Douglas P. , Yueh, Bevan , Sydlowski, Sarah

Mayo Clinic

Otology & Neurotology | December 22, 2025 | Volume: 47 | Issue: 2 | Pages: e158-e163

10.1097/mao.0000000000004700 | PMID 41428499 Get It

Hearing loss is a highly prevalent disease state affecting almost 1 in 5 individuals globally. Growing research shows that untreated or undertreated hearing loss carries significant long-term sequelae, including increased risk of social isolation, depression, and cognitive decline, among other ramifications. Limited awareness and common misperceptions among the general US adult population and primary care providers contribute to low rates of referral to hearing specialty clinics and underutilization of hearing aids, cochlear implants, and other rehabilitative devices. Comprised of diverse membership, the Hearing Health Collaborative (HHC) was formed in May 2021 to identify and overcome challenges impacting good health care practices and public policy on hearing care in connection with healthy aging. This editorial documents a recent outcome of the HHC derived from a structured A3 process. Specifically, initiative 2, a proposal to develop a simple, clinically anchored staging system primarily for use by frontline providers and patients, is presented. Unlike other common disorders that harbor long-term health sequelae, a corresponding pragmatic clinical staging system—leveraging precedent disease staging convention, based on clinically meaningful outcomes and prognosis for acquired hearing loss—does not exist. The development of this staging system will potentially allow for improved communication across providers and patients, facilitate referral pathways, and ultimately enable patient access to timely and appropriate care.
EP133 Short Term Outcomes of Hip Arthroscopy Patients with Acetabular Subchondral Cysts: This Changes Things
Matsuda, Dean, Nho, Shane, Wolff, Andrew, Christoforetti, John J. , Salvo, John P. , Silk, Jake, Martin, RobRoy, McGovern, Ryan P. , Ko, Brandon, Ishimoto, Alyssa, Matsuda, Dean K. , Nho, Shane J. , Carreira, Dominic S.

Mayo Clinic

Journal of Hip Preservation Surgery | December 22, 2025 | Volume: 12 | Issue: Supplement_2 | Pages: ii82-ii82

10.1093/jhps/hnaf069.261 Get It

Abstract Background Some studies have reported more severe chondral pathology and less successful hip arthroscopic outcomes in patients with acetabular subchondral cysts. Purpose The purpose of this study is to report multicenter arthroscopic outcomes of patients with and without acetabular bone cysts. Methods A multicenter matched-pair study was performed with data from a large prospectively collected database. Inclusion criteria were adult patients that had undergone primary unilateral hip arthroscopy for femoroacetabular impingement syndrome (FAIS). The study group was defined by the presence of a superolateral acetabular subchondral cyst on preoperative imaging with > 2mm minimum joint width. 1:1 matching on age, gender, Body Mass Index (BMI), lateral center-edge angle (LCEA), Alpha angle, and rendered arthroscopic treatments of femoroplasty, acetabuloplasty, and labral treatment (i.e., repair, reconstruction, or debridement). Beck chondral grade and minimum 2-year outcomes utilizing VAS for pain, iHOT-12, MCID, SBC, and PASS scores were compared. Results There were 82 patients. The study group had a mean age of 42.16 ± 11.26 years with 48.78% women and a mean BMI of 26.51 ± 4.31 kg/m2. Mean Beck chondral grade was 2.59 ± 1.27 in the study group and 2.70 ± 0.95 in the matched control group (p=0.72). Two-year mean postoperative iHOT-12 scores for the study and control groups were 69.49 ± 24.51 and 73.24 ± 25.16 (p=0.38), while mean postoperative pain VAS were 18.84 ± 18.17 and 20.74 ± 21.39 (p=0.70) The study group reached MCID in 82.93%, SBC in 58.54%, and PASS in 65.85%. The control group reached MCID in 78.05%, SBC in 65.85%, and PASS in 73.17%, with no significant difference between the cohorts (p=0.57, p=0.49, p=0.47, respectively). Discussion/Conclusion Acetabular subchondral cysts are not associated with more chondral pathology than strictly matched controls and may not be a contraindication to hip arthroscopy in patients with FAIS that would otherwise be indicated for this surgery. This finding has pragmatic value in that a significant subset of patients that would otherwise have been denied elective hip arthroscopy may now be potential arthroscopic candidates.
AI-generated videos in medical education: systematic review
Artsi, Yaara , Korfiatis, Panagiotis , Thomas, David C, Nadkarni, Girish N., Klang, Eyal , Sorin, Vera , Glicksberg, Benjamin S. , Thomas, David C. , Nadkarni, Girish N.

Mayo Clinic

BMJ Open Quality | December 22, 2025 | Volume: 14 | Issue: 4 | Pages: e003704

10.1136/bmjoq-2025-003704 | PMID 41429451 Get It

Background Artificial intelligence (AI)-generated text to video is emerging in medical education, but its effectiveness, accuracy and safety remain uncertain. We aimed to synthesise empirical studies evaluating these tools in learner or patient education. Methods A comprehensive search was conducted in MEDLINE/PubMed, Google Scholar, Scopus, Cochrane Review and Web of Science for studies published up to January 2025. Eligible studies evaluated AI-generated text to video for medical or patient education, reporting both quantitative and qualitative outcomes. Two reviewers screened and extracted data. The review adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results Out of 103 identified studies, five studies met the inclusion criteria: four evaluated patient education and one evaluated physician training. Clinical areas were ophthalmology (2/5), plastic surgery (1/5), dysphagia rehabilitation (1/5) and neurosurgical training (1/5). In ophthalmology, control materials outperformed AI-generated videos on image/script accuracy (p<0.005), with similar script-image alignment. In dysphagia rehabilitation, a randomised trial reported improvements in swallowing function and related outcomes with an AI-assisted video game intervention (p<0.001). A plastic surgery study reported greater user preference for a video avatar tool compared with a text chatbot (63.5% vs 28.1%). Across the reviewed studies, samples were small and CIs were rarely reported. Outcome measures were heterogeneous, and meta-analysis was not feasible. Conclusion AI-generated videos can enhance engagement or selected outcomes in certain contexts, yet concerns about accuracy and inconsistent measurement persist. Current evidence is sparse and mixed. Currently, these tools can complement, rather than replace, standard resources until non-inferiority is demonstrated for the prespecified primary outcomes. PROSPERO registration number CRD42025640042.
Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab
Romich, Ellen , Baker, Joshua F. , Riley, Thomas R. , Green, Ian , Rhee, Rennie L. , McAlear, Carol A. , Specks, Ulrich , Smith, Rona , Jayne, David , Merkel, Peter A. , Investigators, for the RITAZAREM, Moreland, Larry W. , Nachman, Patrick H. , Smith, Rona M , Jayne, David , Moreland, Larry W , Specks, Ulrich , Merkel, Peter A , Baker, Joshua F , Investigators, for the RITAZAREM

Mayo Clinic

Arthritis & Rheumatology | December 19, 2025 | Volume: 78 | Issue: 5 | Pages: 1134-1144

10.1002/art.70025 | PMID 41412975 Get It

Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial. Patients aged 15 years or older with AAV and a positive test for anti–proteinase‐3 or anti‐myeloperoxidase‐ANCA who achieved remission after reinduction with rituximab and glucocorticoids were randomized at month 4 to receive continued rituximab or azathioprine for a maintenance period up to 24 months, followed by observation until relapse or up to 48 months. Generalized estimating equations logistic regression identified baseline and time‐varying risk factors for relapse by the next visit for the two study phases: maintenance (months 4–24) and off‐treatment (months 24–48). Results Among 170 patients (median [interquartile range] age 59 [48–68] years, disease duration 5 [2–10] years), 99 relapses occurred (46 during maintenance). During maintenance, musculoskeletal involvement (odds ratio [OR]: 2.8, 95% confidence interval [CI]: 1.1–7.2; P = 0.03) and higher patient global assessment (OR: 1.1, 95% CI: 1.0–1.2; P = 0.04) were associated with relapse. During the off‐treatment phase, presence of CD19 + B cells (OR: 2.5, 95% CI: 1.2–5.1; P = 0.01) and reappearance of ANCA (OR: 3.2, 95% CI: 1.3–7.7; P = 0.01) were each associated with higher relapse risk. Multivariable analysis identified markers of inflammation (changes in platelets, white blood cells, and IgA) associated with relapse. Conclusion Risk factors for relapse in AAV vary by treatment phase. Monitoring markers of inflammation and immune reconstitution may identify patients at risk for relapse, particularly after treatment withdrawal.
Food Insecurity, Burnout, and Social Isolation Among Resident and Fellow Physicians
Thomas, Larissa R. , Satele, Daniel , Akhtar, Saadia, Ripp, Jonathan , Julian, Katherine A. , Sliwka, Diane, Dyrbye, Liselotte N. , Akhtar, Saadia R. , West, Colin P.

Mayo Clinic

JAMA Network Open | December 17, 2025 | Volume: 8 | Issue: 12 | Pages: e2550044

10.1001/jamanetworkopen.2025.50044 | PMID 41405884 Get It

Importance Little is known about food insecurity (FI) among graduate medical education (GME) trainees or how FI might relate to well-being outcomes in this population. Objectives To assess the prevalence of and factors associated with FI among GME trainees and to investigate the associations of FI with well-being outcomes such as burnout and social isolation in this population. Design, Setting, and Participants In this cross-sectional study, a survey was distributed among 3408 resident and fellow physicians at 4 geographically distinct sites within 2 US academic institutions from May 2 to June 21, 2023. All resident and fellow physicians appointed at both institutions were eligible and were invited by email to participate. Main Outcomes and Measures The primary outcome was prevalence of FI. Measurement instruments included a 2-item FI screening tool, a 2-item measure of burnout, items addressing intent to stay at one’s institution, social isolation, and demographic characteristics. Univariable analysis and multivariable Poisson and linear regression were used to characterize prevalence and factors associated with FI and associations with well-being outcomes and intent to stay at the institution. Results Of those eligible, 1656 residents and fellows participated in the survey (a response rate of 48.6%). Of these respondents, 735 of 1458 (50.4%) who indicated their gender identified as men and 365 of 1402 (26.0%) who indicated their parental status reported having children. Of the 1551 respondents who reported their age, 519 (33.5%) were younger than 30 years, 770 (49.6%) were aged 31 to 35 years, 169 (10.9%) were aged 36 to 40 years, and 53 (3.4%) were older than 40 years. Among 1457 respondents indicating their race and ethnicity, the majority were Asian (310 [21.3%]) or White (654 [44.9%]). The overall prevalence of FI was 13.7%. FI proportions differed across training sites, with higher levels in large metropolitan locations (15.6%, 17.0%, and 21.3% for the 3 sites in large metropolitan areas vs 4.5% for the site in a small metropolitan area; P &amp;lt; .001). There were also differences by postgraduate year (16.9% for postgraduate year 1 vs 10.1% for postgraduate year ≥5; P = .003) and race and ethnicity (22.4% for Black or African American trainees compared with 8.4% for White trainees; P = .04). Those with FI were more likely to experience burnout (adjusted relative risk, 1.37 [95% CI, 1.18-1.60]; P &amp;lt; .001), were less likely to consider remaining at their institution after training (adjusted relative risk, 0.81 [95% CI, 0.68-0.98]; P = .02), and had higher social isolation scores (T-score parameter estimate 2.37 [95% CI, 0.89-3.86]; P = .002). Conclusions and Relevance In this cross-sectional study, nearly 1 in 7 GME trainees screened positive for FI. FI was associated with important well-being outcomes including burnout. These findings suggest that academic medical institutions should pursue systemic solutions to address FI among resident and fellow physicians as a means of supporting their well-being.
Myocardial Dysfunction in Primary Mitral Regurgitation
Anand, Vidhu , Bonow, Robert O., Delgado, Victoria , Puthumana, Jyothy , Narang, Akhil , Rigolin, Vera H. , Thomas, James D. , Delgado, Victoria , Nishimura, Rick A. , Cavalcante, João L. , Hung, Judy W. S. , Thomas, James D. , Ranard, Lauren Sharan

Mayo Clinic

JAMA Cardiology | December 17, 2025 | Volume: 11 | Issue: 2 | Pages: 199

10.1001/jamacardio.2025.4561 | PMID 41405892 Get It

Importance Primary mitral regurgitation (MR) is a prevalent valvular lesion. Current American College of Cardiology/American Heart Association guidelines include class I recommendations for intervention for severe primary MR at the onset of symptoms, significant left ventricular (LV) enlargement (end-systolic dimension ≥40 mm), or dysfunction (ejection fraction ≤60%), with a class IIA recommendation for mitral valve repair when performed at an experienced surgical center. Recent data suggest a survival penalty when waiting for class I surgical guideline indications, and novel markers of decompensation are under investigation. Observations Comprehensive assessment of MR severity using echocardiography is critical, and when warranted, cardiac magnetic resonance (CMR) is complementary. Assessment of LV size and function, as well as serial changes in both, is crucial for determining timing of surgery. New-onset atrial fibrillation, left atrial enlargement, pulmonary hypertension, and exercise-induced changes in LV function should also be considered in borderline scenarios. The roles of LV volumes, global longitudinal strain, CMR-derived measures of myocardial dysfunction, and cardiac biomarkers are worthy of further investigation regarding consideration for early surgical intervention. Conclusions and Relevance A more refined approach incorporating assessment of extravalvular cardiac injury, novel imaging markers, and biomarkers is needed to optimize surgical timing in primary MR. Further research is warranted to validate these emerging parameters and refine guidelines to improve patient outcomes.
Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26
Ioakeim‐Ioannidou, Myrsini, Yeap, Beow Y., Soetan, Z. , Hegazy, Rana , Todary, Engy S. , Tejada, Athena, Adams, Judith E., Kooy, Hanne M., Zieminski, Stephen, Nielsen, G. Petur, Hung, Yin P. , Rosenberg, Andrew , Shankar, Ganesh M. , Cunnane, Mary E. , Chang, Yuh-Shin , Gardner, Paul A. , Giap, Fantine , DeLaney, Thomas F. , Hug, Eugen B., MacDonald, Shannon M. , Packard, Daniel, Hung, Yin P , Kim, Daniel W. , Packard, Daniel George , Hegazy, Rana, Adams, Judith, Depauw, Nicolas , Rosenberg, Andrew, Tobert, Daniel G , Curry, William T. , Coté, Gregory M. , Kelly, Hillary R. , Chen, Yen‐Lin , Liu, Kevin X , Shih, Helen A.

Mayo Clinic

Neuro-Oncology | December 17, 2025 | Volume: 28 | Issue: 4 | Pages: 968-977

10.1093/neuonc/noaf289 | PMID 41414803 Get It

Abstract Background To determine if dose escalation improves outcomes for chondrosarcomas (CHS) of the base of the skull (BOS) and the cervical spine (CS). Methods A prospective, randomized, dose-escalation trial was designed for patients with CHS of the BOS and CS. Patients were randomly assigned to 70 Gy (RBE) or 76 Gy (RBE). The primary endpoint was local failure (LF). Secondary endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and treatment-related toxicities. Results Between 1987 and 2007, 105 patients were randomized, median follow-up was 29.2 years (IQR, 26.7-32.4). Forty-six patients were assigned to 70 Gy (RBE) and 59 were assigned to 76 Gy (RBE). LF at 5-, 10-, and 20 years were 7%, 9%, and 11% for 70 Gy (RBE), and 10%, 15%, and 19% for 76 Gy (RBE) (P = .16). Like LF rates, there was no benefit in dose escalation for OS (P = .28) and CSS (P = .22). Progression-free survival at 5-, 10-, and 20 years was 93%, 89%, and 77% for the low-dose group and 83%, 71%, and 59% for the high-dose group (P = .069). Late RT injury ≥ grade 3 was reported in a total of 19 (18%) patients across both dose levels, with 11% in the low-dose group and 24% in the high-dose group (P = .13). Conclusions This is the first and largest trial of patients with grade I/II BOS and CS CHS evaluating dose escalation for tumor control. Proton-based RT is effective and safe for these tumors, but there is no apparent benefit in dose escalation. Clinical Trial Information NCT00592748.
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH -wildtype
Lachance, Daniel H , Decker, Paul A. , Kosel, Matthew , Odukoya, AbdulLateef, Maqbool, Muhammad Asad , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Odukoya, Lateef A , Kollmeyer, Thomas M. , Praska, Corinne E, Odukoya, AbdulLateef A, Tobin, William Oliver, Galanis, Evanthia , Giannini, Caterina , Vaubel, Rachel A, Ida, Cris M, Jenkins, RB , Eckel-Passow, Jeanette E , Odukoya, Lateef A , Lachance, Daniel , Decker, Paul A. , Drucker, Kristen , Praska, Corinne , Kizilbash, Sani H. , Shafqat, Shameel , Tobin, W. Oliver , Parney, Ian F. , Burns, Terry C. , Galanis, Evanthia , Giannini, Caterina , Vaubel, Rachael A. , Ida, Cristiane M.

Mayo Clinic

Neuro-Oncology Advances | December 16, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf260 | PMID 41908146 Get It

Abstract Background Glioblastoma IDH-wildtype (GBM) may be diagnosed histologically (hGBM) or based on molecular features when microvascular proliferation and histologic necrosis are absent (mGBM). Clinical and radiographic distinction between hGBM and mGBM remains unclear. Methods 101 hGBM cases were matched to 109 mGBM cases by age, sex, year of diagnosis, and TERT promoter mutation (TERTp) status. Clinical outcome, radiographic, and molecular features were compared across mGBM and hGBM. Results Median time from first MRI to diagnosis was longer for mGBM versus hGBM (34 vs 7 days, p &lt; .001). mGBM more often presented with seizures (51% vs 26%, p &lt; .001), gliomatosis pattern (12% vs 2%, p = .005), basal ganglia involvement (17% vs 0%, p &lt; .001). Contrast enhancement appeared on MRI for 98% (96/98) of hGBM and 50% (54/107) of mGBM (p &lt; .001). mGBM with non-enhancing MRI were rarely multifocal (2% vs 30%, p &lt; .001). mGBM harbored fewer total copy number alterations (median 20 vs 16.5, p = .029), less often had EGFRamp (34% vs 48%, p = .051), isolated chromosome 10 loss (84% vs 96%, p = .013), and CDKN2A/B homozygous deletion (56% vs 77%, p = .005). Median overall survival was longer for mGBM (2.16 vs 1.44 years, p &lt; .001), and for mGBM without MRI contrast enhancement versus hGBM with enhancement (3.11 vs 1.62 years, adjusted p = .003). mGBM without +7/−10 or without CDKN2A/B homozygous deletion had longer survival and time-to-progression versus hGBM with these alterations. Conclusion mGBM with MRI enhancement may represent undersampled or early/evolving hGBM. mGBM that are non-enhancing, present with seizures, prolonged time to diagnosis, absent CDKN2A/B alteration or +7/−10 may represent other IDH-wildtype entities.